Free Trial

Geron (GERN) Stock Forecast & Price Target

Geron logo
$4.02 +0.03 (+0.75%)
(As of 11/21/2024 ET)

Geron - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
10

Based on 11 Wall Street analysts who have issued ratings for Geron in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 1 has given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for GERN.

Consensus Price Target

$7.05
75.37% Upside
According to the 11 analysts' twelve-month price targets for Geron, the average price target is $7.05. The highest price target for GERN is $10.00, while the lowest price target for GERN is $4.50. The average price target represents a forecasted upside of 75.37% from the current price of $4.02.
Get the Latest News and Ratings for GERN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Geron and its competitors.

Sign Up

GERN Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.05$6.94$7.07$4.75
Forecasted Upside75.37% Upside73.18% Upside55.76% Upside143.59% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Buy

GERN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GERN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Geron Stock vs. The Competition

TypeGeronMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside75.37% Upside26,677.67% Upside8.51% Upside
News Sentiment Rating
Positive News

See Recent GERN News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/5/2024HC Wainwright
2 of 5 stars
E. Bodnar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$8.00 ➝ $8.00+88.24%
10/16/2024Scotiabank
5 of 5 stars
G. Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$6.00+43.20%
9/9/2024Leerink Partnrs
5 of 5 stars
F. Khurshid
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/9/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$7.00+64.71%
8/9/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00+30.43%
8/8/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$8.00+73.91%
6/10/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$9.00+87.50%
6/10/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$6.00 ➝ $7.00+48.94%
4/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$4.50+8.70%
4/29/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$10.00+163.85%
3/15/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$4.00 ➝ $5.00+60.00%
1/9/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Patel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$4.00 ➝ $5.00+100.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:59 PM ET.


GERN Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Geron is $7.05, with a high forecast of $10.00 and a low forecast of $4.50.

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There is currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GERN shares.

According to analysts, Geron's stock has a predicted upside of 75.37% based on their 12-month stock forecasts.

Over the previous 90 days, Geron's stock had 1 upgrade by analysts.

Geron has been rated by research analysts at HC Wainwright, Leerink Partners, Leerink Partnrs, and Scotiabank in the past 90 days.

Analysts like Geron more than other "medical" companies. The consensus rating for Geron is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GERN compares to other companies.


This page (NASDAQ:GERN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners